ReviewJournal of clinical medicine2026
Use of Artificial Intelligence in Rheumatoid Arthritis: Advancements and Novel Perspectives.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that can cause severe joint damage and disability. The management of RA patients has evolved significantly over the past few decades due to improved detection of early disease progression and the initiation of targeted advanced treatments. However, several gaps remain, including disease risk assessment, early diagnosis, phenotypic identification, and risk of treatment failure. These gaps could potentially be addressed by the application of artificial intelligence (AI), defined as the ability of a machine to mimic intelligent human behavior, using machine learning and deep learning models. By analyzing various types of data, including clinical, laboratory, and imaging data, omics, demographics, and data from sensor applications or wearable technologies, it may be possible to improve the management of RA patients, as demonstrated by several studies. However, limitations related to interindividual variability, small datasets, study designs, and intrinsic model bias remain, making it difficult to generalize findings to larger cohorts of RA patients. The aim of this narrative review is to discuss the potential uses and limitations of AI-based algorithms in RA patients in light of the most recent scientific evidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.